AI adoption in clinical radiology: 4 ups, 4 downs

If healthcare AI is to improve care and efficiency in clinical practice across medicine, its proponents in radiology must implement it in a structured manner.

Why? Because only with structured AI implementation can the emerging technology’s utility be assessed with empirical evidence. And because radiology is the medical specialty furthest along with AI.

So suggest researchers at Utrecht University in the Netherlands who formally interviewed 24 healthcare professionals at seven Dutch hospitals. The participant cohort was mostly made up of radiologists but also included some data scientists, innovation managers and others.

The researchers’ objective was to pinpoint factors helping AI’s cause in clinical radiology as well as those holding it back.

Reporting their findings in a study published online May 26 in European Radiology, corresponding author Charisma Hehakaya and colleagues nail down the opposing forces to four primary factors each:

Key facilitating factors:

  1. Pressure for cost containment throughout healthcare
  2. High expectations of AI’s potential added value
  3. Presence of hospital-wide innovation strategies
  4. Presence of a “local champion”

Key hindering factors:

  1. Inconsistent technical performance of AI applications
  2. Unstructured implementation processes
  3. Uncertain added value for clinical practice of AI applications
  4. Large variance in acceptance and trust of direct (radiologists) and indirect (referring clinicians) adopters

In their discussion, the authors comment that the need for hard data supporting adoption of innovations in medicine is, by now, a given in the era of evidence-based healthcare.

“Scientific evidence is an important determinant of innovation implementation for practitioners, a finding that also appears to hold for AI in radiology,” they write. “It thus follows that AI applications for radiology reflect a trend in the field of medical imaging to engage with technologies that have yet to prove their promises of contributing to the improvement of the quality or efficiency of healthcare.”

The study is posted in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.